PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of canrestreatCancer Research and Treatment
 
Cancer Res Treat. 2004 December; 36(6): 389–394.
Published online 2004 December 31. doi:  10.4143/crt.2004.36.6.389
PMCID: PMC2843882

Photodynamic Effects of Radachlorin® on Cervical Cancer Cells

Su-Mi Bae, MS.,1 Yong-Wook Kim, M.D., Ph.D.,2 Joon-Mo Lee, M.D., Ph.D.,2 Sung-Eun Namkoong, M.D., Ph.D.,2 Sei-Jun Han, M.D., Ph.D.,2 Jong-Ki Kim, Ph.D.,3 Chang-Hee Lee, Ph.D.,4 Heung-Jae Chun, Ph.D.,1 Hyun-Sun Jin, Ph.D.,1 and Woong-Shick Ahn, M.D., Ph.D.corresponding author2

Abstract

Purpose

Photodynamic therapy (PDT) is a novel treatment modality, which produces local tissue necrosis with laser light following the prior administration of a photosensitizing agent. Radachlorin® has recently been shown to be a promising PDT sensitizer. In order to elucidate the antitumor effects of PDT using Radachlorin® on cervical cancer, growth inhibition studies on a HPV-associated tumor cell line, TC-1 cells in vitro and animals with an established TC-1 tumor in vivo were determined.

Materials and Methods

TC-1 tumor cells were exposed to various concentrations of Radachlorin® and PDT, with irradiation of 12.5 or 25 J/cm2 at an irradiance of 20 mW/cm2 using a Won-PDT D662 laser at 662 nm in vitro. C57BL/6 mice with TC-1 tumor were injected with Radachlorin® via different routes and treated with PDT in vivo. A growth suppression study was then used to evaluate the effects at various time points after PDT.

Results

The results showed that irradiation of TC-1 tumor cells in the presence of Radachlorin® induced significant cell growth inhibition. Animals with established TC-1 tumors exhibited significantly smaller tumor sizes over time when treated with Radachlorin® and irradiation.

Conclusion

PDT after the application of Radachlorin® appears to be effective against TC-1 tumors both in vitro and in vivo.

Keywords: Radachlorin®, Photodynamic therapy (PDT), Cervical cancer, TC-1 cell

INTRODUCTION

PDT is a novel treatment modality, which produces local tissue necrosis with laser light following the prior administration of a photosensitizing agent (1~4). Photosensitizers are applicable for the treatment of cancer as well as nontumoral diseases, such as psoriasis (5), bacterial and viral eradication (6,7), and for tumor detection (8). During the last several years, a whole range of dyes, such as Photofrin (USA, Canada), Photoscan (Germany), HPD (China), Photogem (Russia), Benzoporphyrin derivative (Canada), 5-aminolevulenic acid (ALA, Europe and USA) and Aspartate chlorine E6 (Japan), to name but a few, have been used as photosensitizers for a wide range of malignant tumors and non-malignant diseases (9~18). The disadvantages of using photosensitizers are poor tumor selectivity and prolonged photosensitization, which have yet to be overcome. Therefore, the application of PDT still remains limited due to the limited penetration of light in tissues, the chances of photosensitization of normal tissues and photosensitivity of the skin, which can last for 4~6 weeks after treatment (19,20). Recently, Radachlorin®, a derivative of the well-known water soluble green pigment chlorophyll α, has been shown to be a promising PDT sensitizer, and was first introduced as potential drugs by E. Snyder in 1942 (21). Radachlorin® as a drug substance represents an aqueous solution of three chlorins, including sodium chlorin e6 (90~95%) as the major ingredient, which is used as a carrier and solubilizing ligand (Fig. 1A), sodium chlorin p6 (5~7%) (Fig. 1B), and a third chlorin, which can not be disclosed (1~5%), both as pharmacogenic ingredients (Online at www.radapharma.ru). Thus, Radachlorin® (Fig. 1) is a complex natural photosensitizer as a drug accumulating and efficiently destroying tumors upon irradiation (662 nm). It has maximal tumor uptake 3~5 h post injection, with a high tumor-to-tumor tissue ratios and a clearance period of about 24~48 h (21). However, there have only been a few studies on the PDT effects of Radachlorin® in cervical cancer, although there have been several studies on Chlorin e6, which is a major component of Radachlorin®. Therefore, in this study, the PDT induced antitumor effects of Radachlorin® were evaluated in cervical cancer cells and an animal model.

Fig. 1
Structure of Radachlorin®'s major component - sodium chlorin e6 (A) and one of the minor components - sodium chlorin e6 (B).

MATERIALS AND METHODS

1) Photosensitizer

The Radachlorin® was purchased from the RADA-PHARMA group (RADA-PHARMA Co, Ltd., Moscow, Russia), which was stable in solutions at 0±8[degree celsius] in the dark.

2) Cell culture conditions

A mouse lung cancer cell line of TC-1 cells, which was derived from primary epithelial cells of C57BL/6 mice cotransformed with HPV-16 E6 and E7, as well as c-Ha-ras oncogenes (from Cancer Research Center, Seoul National University, Korea), were cultured on RPMI 1640 media (Gibco BRL, Rocksville, MD) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL). Streptomycin/penicillin (Gibco BRL), L-glutamine (Gibco BRL), 2.2 mg/ml sodium bicarbonate (Sigma, St. Louis, MO) 0.4 mg/ml G418 disulfate (Duchefa, Netherlands) were added to the culture medium and the cells maintained at 37[degree celsius] in a 5% CO2 humid environment.

3) Immunization of mice

The female C57BL/6 mice (6~8 weeks old) were purchased from DaeHan Biolink (Daejon, Korea), and maintained under pathogen-free conditions. A TC-1 tumor animal model was established as previously reported (22). Briefly, 0.1 ml PBS suspension (3×106 cells/ml) of TC-1 cells was injected subcutaneously into the belly of the mice using a syringe. After the cancer cells had made a tumor size of 9 mm, the TC-1 cell implanted mice were then either i.v. or i.p. injected with 40 mg of Radachlorin®/kg of body weight (b.w.), respectively, and PDT performed.

4) PDT

The PDT was carried out using a laser apparatus generated by a diode (Won-PDT D662, Won Technology, Daejeon, Korea) equipped with high power laser diode module, with a built in temperature control system, optical fiber bundle and fiber test module. The wavelength was set at 662±3 nm. The duration of the light irradiation, under PDT treatment, was calculated taking into account the empirically found effective dose of light energy in J/W.

5) Radachlorin® uptake by TC-1 cells in vitro

TC-1 cells were inoculated into 6 well plates, with cover glasses, in a volume of 2 ml (5×104 cells/well) for a stationary culture. Twenty-four hours later, Radachlorin® (2.5, 5, 10, 20 and 50µg/ml) was added in a volume of 2 ml. After a predetermined time, the Radachlorin® solution was discarded; the TC-1 cells were washed twice with PBS and fixed with 1% paraformaldehyde. The cells were then washed again with distilled water, the cover glasses removed from the 6 well plates and mounted on slide glass. Confocal microscope (MRC 1024, Bio-RAD, Hercules, CA) measurements were performed at emission and excitation wavelengths of 545 and 600 nm.

6) MTT assay

TC-1 cell lines were inoculated into a 96-well, flat-bottomed microplate at a volume of 100µl (2×103 cells/well) for a stationary culture. Twenty-four hours later, the medium was removed, and the cultures washed three times in PBS. Various concentrations (0, 2.5, 5, 10 and 20 cg/ml) of Radachlorin® were then added in a volume of 100µl/well. Three or 12 h later, the Radachlorin® solution was discarded, the cultures washed a further three times with PBS and medium added to a volume of 100µl/well. The cultures were then subjected to laser irradiation (12.5 or 25 J/cm2), followed by the MTT assay to evaluate their sensitivity to PDT (Radachlorin®). For the MTT assay, 20µl of MTT reagent (5 mg/ml) was added to each cell culture well and cultured for 4 h. 200µl of DMSO was added to the culture, shaken for 10 min and the absorbance measured with an ELISA-reader at 570 nm. Measurements were performed for 6 days after the laser irradiation. Samples were assayed in triplicate, and the mean used as the measured value. The amount of Radachlorin® was also compared with the cancer cell lines.

7) Inhibition of TC-1 tumor growth in vivo

Animals were randomized into four groups (ten animals in each group): ([diamond]) control (untreated); (Δ) Radachlorin® only; (▲) irradiation only; (○) Radachlorin® 40 mg/kg b.w. intravenous (i.v.) injection and irradiation; (●) Radachlorin® 40 mg/kg b.w. intraperitoneal (i.p.) injection and irradiation. The TC-1 cell implanted mice were either i.v. or i.p. injected with 40 mg of Radachlorin®/kg of b.w., respectively. The photodynamic treatment was carried out 24 h after the drug administration using 662 nm radiation from a diode laser. A power density of 2 W/cm2 and irradiation time of 150 sec was used. The tumor sizes were evaluated for 9 days by measuring two perpendicular diameters with calipers, and the tumor size calculated based on the average dimensions. The tumors were removed on the days indicated, and frozen to -70[degree celsius] until required for analysis.

RESULTS

1) Observation of Radachlorin® uptake by TC-1 cells

Fig. 2 shows the confocal microscopy of TC-1 cells after 24 h exposure to various concentrations of Radachlorin®. TC-1 cells were seen to contain Radachlorin®, which was excited to emit red to a confocal microscope. The luminescence of each cell was higher, in a Radachlorin® dose dependent manner (A-F). The Radachlorin® in the TC-1 cells showed no cytotoxicity, even with a higher concentration of 50µg/ml (data not shown).

Fig. 2
Development of Radachlorin®-mediated cellular uptake in TC-1 cells. Radachlorin® was incubated at concentrations of 0µg/ml (A), 2.5µg/ml (B), 5µg/ml (C), 10µg/ml (D), 20µg/ml (E) and 50µg/ml ...

2) Intracellular localization of Radachlorin®

It is important to determine the biological mechanism of action of a drug; therefore, the intracellular distribution of Radachlorin® was determined in TC-1 cells. The intracellular localization of TC-1 cells after 12 h incubation with 5µg/ml of Radachlorin® was measured by confocal microscopy (Fig. 3). The fluorescence was emitted from well-defined spots in the cytoplasm, and diffused fluorescence seen in the entire cytoplasm. The fluorescence micrographs suggested association of with the plasma membrane.

Fig. 3
Intracellular localization of TC-1 cells after 12 h of exposure to 5µg/ml Radachlorin®, as measured by confocal microscopy (A-B) (Magnification×12,000). The fluorescence was emitted from well-defined spots in the cytoplasm, and ...

3) Antitumor effect of PDT using Radachlorin® in vitro

The efficacy of cell damage after PDT with Radachlorin® was further quantified by the MTT assay. The results of the experiment with TC-1 cells are shown in Fig. 4 (A-D). TC-1 cells incubated with various concentration of Radachlorin® and irradiated with laser showed significantly reduced cell viability with increasing light dose (B). However, when TC-1 cells were incubated with 2.5µg/ml of Radachlorin® for 3 h, and then irradiated with 25 Jcm2, the cell viability increased compare to the other Radachlorin® dosed cells (A). At the lowest light dose, 12.5 J/cm2, this experiment induced an increased cell viability when Radachlorin® was dosed at 2.5µg/ml and incubated for 3 and 12 h (C & D). Even though with a lower light dose exposure (12.5 J/cm2); the cell viability was significantly lower with an exposure time of Radachlorin® of 24 h than with 3 or 12 h (data not shown). Therefore, the optimal experimental drug dose of Radachlorin® seems to be 2.5µg/ml for 3 h or 12 h, with irradiation of 12.5 or 50 J/cm2, against TC-1 cells.

Fig. 4
Cell growth-inhibitory effects of PDT on TC-1 cells in vitro. Cells (2×103 cells/well) were cultured overnight in 96-well plates, in triplicate, and incubated with Radachlorin® for 3 or 12 h, with irradiation of 12.5 or 25 J/cm2 at an ...

4) Measurement of Photodynamic effects in vivo

The antitumor activity of PDT using Radachlorin® in C57BL/6 mice with TC-1 tumors was determined, as shown in Fig. 5. In the Irradiation and Radachlorin® only group, the tumor sizes increased over the time period. It was observed that the control group, which showed a linear increase in tumor size over the time, was similar. The PDT only group showed no cytotoxicity in the TC-1 tumor lesions. Radachlorin® itself also had no toxicity on mice (data not shown). In the PDT using Radachlorin® treatment group, when the C57BL/6 mice with TC-1 tumors were PDT irradiated using 40 mg of Radachlorin®/kg b.w. (i.p.), the tumor size was significantly reduced compared to the other experimental and PDT using 40 mg of Radachlorin®/kg b.w. (i.v.) groups. PDT with an i.p. injection of Radachlorin® group showed improved antitumor effects over those with an i.v. injection.

Fig. 5
Antitumor effect of PDT using Radachlorin® in vivo. Tumor growth curves of mice treated using several protocols. ([diamond]), control (untreated); (Δ), Radachlorin® only; (▲), irradiation only; (○), Radachlorin® ...

DISCUSSION

Radachlorin® has recently been shown to be a promising PDT sensitizer (23), with a report showing the photodynamic effect on novel chlorin e6 derivatives, including Radachlorin®, on a single nerve cell (24). The study demonstrated that Radachlorin® was a most potent photosensitizer, comparable with Meso-[tetrakis(m-hydroxyphenyl)]chlorin (mTHPC), a well-known photosensitizer (24). In this study, TC-1 cells were shown to contain Radachlorin® in a dose dependent manner, which did not affect the viability of cells compared with the values of non-Radachlorin incubated cells (data not shown). Diffused fluorescence was found in the entire cytoplasm. Localization of Radachlorin® up take by TC-1 cells was not studied in detail in the present study. A previous report has shown that localization of intracellular photosensitizer depends on the lipophilicity and amphiphilicity of the photosensitizer (25). When incubated with cells, molecules of the photosensitizer were first adsorbed onto the plasma membrane and then penetrated into the cells. Hydrophilic photosensitizers that cannot cross the plasma membrane penetrated into the cell by means of pinocytosis, with taken up into the vesicles, endosomes and lysosomes. Following photodamage of these organelles, photosensitizers enter the cytosol and sensitize different cellular structures. Our data showed that Radachlorin® was seen to be adsorbed into the entire cytosol.

In a previous study, a PC12 (pheochromocytoma) cell line and the MTT test were used for in vitro assays, and laser light of 662 nm for Radachlorin® at the doses of 50 J/cm2 was irradiated (21). Radachlorin® did not show toxicity on the PC12 cell lines without irradiation, except with very high concentrations. Thus, in vitro Radachlorin® is a less toxic and more efficient photosensitizer upon irradiation than the other photosensitizers available (www.radapharma.ru). Our data also demonstrated that Radachlorin® treatment showed no cytotoxicity on TC-1 cells (data not shown), which supports the findings from previous experiments (21). In the irradiation treated group without Radachlorin® the accumulation also had no antitumor effect on mice with TC-1 tumors, as shown in Fig. 5. Therefore, these data suggested that Radachlorin® and PDT should be used together for the efficient destruction of the tumor lesions in TC-1 tumors. Pharmacokinetics and biodistribution studies (21, www.radapharma.ru) in mice have shown that maximal tumor accumulation of Radachlorin® was achieved 5 and 0.5 h after intraperitoneal and intravenous administrations, respectively. The highest contrast with Radachlorin® was observed at 18 h after the intraperitoneal administration with the tumor-to-muscle ratio of about 32, and tumor-to-skin ratio of about 44. The full clearance period was been found to be 48 h after the intraperitoneal administration via all routes of administration, a very important point as regards the problem of skin phototoxicity (23). Therefore, Radachlorin® shows excellent characteristics for use with PDT (21). Our preexperimental data were similar; however, the results have not been shown in this paper. Our data also support the advantageous use of Radachlorin® with PDT (data not shown). in vivo experimental data (Fig. 5) suggest that the PDT with an i.p. injection of Radachlorin® group showed an improved antitumor effect over those with an i.v. injection. This was probably due to the mechanisms of Radachlorin® accumulation via the two injection routes being different, but these remain for further study. Further study will be critical to follow up the tumor size and tumor survival in the long term, more than 60 days, to obtain a conclusive result.

CONCLUSIONS

PDT using Radachlorin® might have significant advantages in the selectively killing of tumor lesions in TC-1 tumors, both in vitro and in vivo.

References

1. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145–157. [PubMed]
2. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150:S146–S156. [PubMed]
3. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumors. J Photochem Photobiol B. 1997;39:1–18. [PubMed]
4. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889–905. [PubMed]
5. Berns MW, Rettenmaier M, McCullough J, Coffey J, Wile A, Berman M, et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative. Lasers Surg Med. 1984;4:73–77. [PubMed]
6. Nir U, Laden H, Malik Z, Nitzan Y. In vivo effects of porphyrins on bacterial DNA. J Photochem Photobiol B. 1991;11:295–306. [PubMed]
7. Rywkin S, Ben-Hur E, Malik Z, Prince AM, Li YS, Kenney ME, et al. New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates. Photochem Photobiol. 1994;60:165–170. [PubMed]
8. Andersson-Engels S, Johansson J, Svanberg K, Svanberg S. Fluorescence imaging and point measurements of tissue: applications to the demarcation of malignant tumors and atherosclerotic lesions from normal tissue. Photochem Photobiol. 1991;53:807–814. [PubMed]
9. Bodner K, Bodner-Adler B, Wierrani F, Kubin A, Szolts-Szolts J, Spangler B, et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. Anticancer Res. 2003;23:1785–1788. [PubMed]
10. Barnett AA, Haller JC, Cairnduff F, Lane G, Brown SB, Roberts DJ. A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer. 2003;103:829–832. [PubMed]
11. Keefe KA, Tadir Y, Tromberg B, Berns M, Osann K, Hashad R, et al. Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. Lasers Surg Med. 2002;31:289–293. [PubMed]
12. Hillemanns P, Korell M, Schmitt-Sody M, Baumgartner R, Beyer W, Kimmig R, et al. Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Int J Cancer. 1999;81:34–38. [PubMed]
13. Pahernik SA, Botzlar A, Hillemanns P, Dellian M, Kirschstein M, Abels C, et al. Pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia. Int J Cancer. 1998;78:310–314. [PubMed]
14. Nakamura H, Suzuki Y, Takeichi M, Saito T, Takayama M, Aizawa K. Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines. Int J Gynecol Cancer. 2002;12:177–186. [PubMed]
15. Krimbacher E, Zeimet AG, Marth C, Kostron H. Photodynamic therapy for recurrent gynecologic malignancy: a report on 4 cases. Arch Gynecol Obstet. 1999;262:193–197. [PubMed]
16. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20:3–7. [PubMed]
17. Levy JG, Obochi M. New applications in photodynamic therapy. Introduction. Photochem Photobiol. 1996;64:737–739. [PubMed]
18. Bae SM, Huh SW, Park EK, Lee KH, Lee JM, Namkoong SE, et al. Photogem induces necrosis in various uterine cervical cancer cell lines by PDT. Cancer Res Treat. 2003;35:549–556.
19. Wooten RS, Smith KC, Ahlquist DA, Muller SA, Balm RK. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg Med. 1988;8:294–300. [PubMed]
20. Dartsch PC, Coppenrath E, Coppenrath K, Ischinger T. Photodynamic therapy of vascular stenosis: results from cell culture studies on human endothelial cells. Coron Artery Dis. 1993;4:207–213. [PubMed]
21. PDT Korea Co., LTD. Handbook of Clinical PhotoDynamic Therapy. PDT Korea Co., LTD; 2001. pp. 1–70.
22. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–26. [PubMed]
23. Privalov VA, Lappa AV, Seliverstov OV, Faizrakhmanov AB, Yarovoy NN, Kochneva EV, et al. Clinical trials of a new chlorin photosensitizer for photodynamic therapy of malignant tumors. Proc SPIE. 2002;4612:178–189.
24. Uzdensky AB, Dergacheva OY, Zhavoronkova AA, Reshetnikov AV, Ponomarev GV. Photodynamic effect of novel chlorin e6 derivatives on a single nerve cell. Life Sci. 2004;74:2185–2197. [PubMed]
25. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol. 1996;20:109–129. [PubMed]

Articles from Cancer Research and Treatment : Official Journal of Korean Cancer Association are provided here courtesy of Korean Cancer Association